Skip to main content
OpenTrials
Completed

NCT Number: NCT02568709

Oxytocin MEG Study

The specific aim of this proposal is to investigate the neurophysiological mechanisms of oxytocin's (OT) prosocial effects in patients with schizophrenia and healthy subjects using magnetoencephalography.

Hypothesis A: When OT is administered to patients with schizophrenia, fear-related amygdala hyperreactivity and fusiform gyrus (FG) and anterior cingulate cortex (ACC) hypoactivity will be normalized.

Hypothesis B: When OT is administered to patients with schizophrenia, the decreased functional connectivity (FC) between the amygdala, FG, and ACC will be normalized.

By elucidating the neurophysiological mechanisms of OT administration on emotional face processing, investigators will bee able to:

1. understand the pathophysiology of the functionally debilitating social cognitive deficits of schizophrenia, 2. test the efficacy of OT in normalizing the neural abnormalities underlying these social deficits, and 3. develop and optimize novel treatments for these currently untreatable deficits.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Early Phase 1

Primary location

University of California, San Francisco

San Francisco, California, 94143, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for Patients:

  • 18-40 years of age
  • Male
  • Must comprehend English
  • Meet DSM-IV criteria for schizophrenia, schizophreniform or schizoaffective disorder
  • None or only minor changes to medications in the past week
  • Able to use nasal spray
  • Must be capable of providing informed consent
  • Clinically stable

Inclusion criteria

for Healthy Controls:

  • 18-40 years of age
  • Male
  • Must comprehend English
  • No diagnosis of mental disorder according to DSM-IV TR
  • Able to use nasal spray
  • Must be capable of providing informed consent
  • Clinically stable

Exclusion criteria

  • Female
  • Active substance abuse or dependence as determined by a Urine Toxicology Drug Screening
  • DSM-IV diagnosis of any disorder other than schizophrenia
  • Medical conditions (atrophic rhinitis, recurrent nose bleeds and cranial surgical procedures (hypophysectomy), congestion or sinus problems that could interfere with the study as per the opinion of the investigator
  • Hearing deficits
  • A pacemaker, extensive dental work, or any magnetic metal implants
  • Any history of severe brain trauma

Treatment and study plan

Oxytocin

Drug

40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.

Other names: Syntocinon

Saline Nasal Spray

Drug

40 IU of the saline nasal spray will be administered once at the beginning of the visit.

Other names: Placebo

Primary outcomes

  1. Change in MEG neural activation patterns

    Time frame: Oxytocin and placebo administration days at least 1-week apart

    During tasks in which participants will see and hear various stimuli, investigators will measure the change in neural activity in the amygdala, the dorsal anterior cingulate cortex, as well as the fusiform gyrus using the MEG scanner.

Secondary outcomes

  1. Change in performance on Facial Recognition Task

    Time frame: Oxytocin and placebo administration days at least 1-week apart

    In the Facial Recognition Task, subjects will be presented with various computerized emotional stimuli and will be asked to make a choice. Participants will then respond to the stimuli by pressing a either left or right on the control box and their reaction time will be measured.

  2. Change in performance on International Affective Picture System (IAPS) task

    Time frame: Oxytocin and placebo administration days at least 1-week apart

    In the IAPS Tasks, subjects will view images of people, objects, and scenes from the IAPS (International Affective Picture System). Participants will then respond by pressing a either left or right on the control box to chose a number from 1 (i.e. least disturbing) to 9 (i.e. most disturbing) and their reaction time will be measured.

  3. UCLA Loneliness Scale

    Time frame: 1 day

    The UCLA Loneliness Scale assesses the loneliness level of participants. It is a 20-item scale where responses are measured from O ("I often feel this way") to N ("I never feel this way").

  4. Experiences in Close Relationships-Relationship Structures (ECR-RS) Questionnaire

    Time frame: 1 day

    The ECR is used to evaluate the construct of adult attachment. The scale involves 36 itemized statements split into four parts, each part referring to a different attachment figure. Participants rank each item using a 7-point likert scale.

  5. Childhood Trauma Questionnaire (CTQ)

    Time frame: 1 day

    The CTQ is a brief survey of 6 early traumatic experiences, including death, divorce, violence, sexual abuse, illness or other. The scale determines and assesses an individual's understanding of their childhood trauma, if applicable.

  6. Parental Bonding Instrument (PBI)

    Time frame: 1 day

    The PBI measures fundamental parenting styles as perceived the child. The questionnaire is retrospective in that it asks the adult participant to answer the questions based on how they remember their parents to be during up until they were 16 years old. The measure is completed for both mothers and fathers separately. There are 25 questions where half the questions are focused on how the parent cared for them and half are focused on how the parents protected them. A likert scale is used to measure responses where 1 is agree (i.e. very like) and 4 is disagree (i.e. very dislike).

  7. Emotional Quotient Scale (EQS)

    Time frame: 1 day

    The EQ is a 60-item self-report questionnaire that is designed to measure empathy in adults. Participants use a 4 item likert scale to record their responses (1=definitely agree, 4= definitely disagree).

  8. Fagerstom Nicotine Dependence Test

    Time frame: 1 day

    The FNDT is the standard measure of an individual's physical addiction to nicotine. The test contains six items to evaluate the quantity of cigarette consumption, the compulsion to use, and dependence.

  9. Quality of Life Scale (QLS)

    Time frame: 1 day

    The QLS is a 21-item clinical rating scale where the interviewer rates the participant's responses on a scale of 1-6 where 6 indicates no impairment. In this study, an abbreviated version of the QLS is used that includes 9 of the 21 items. The 9 items are each derived from the sections examining interpersonal relations, occupational role functioning, intrapsychic foundations, and common objects.

  10. Social Functioning Scale (SFS)

    Time frame: 1 day

    The SFS is designed to assess a subject's social skills and performance, and to measure functions that are of importance for schizophrenic patients. It is a 79-item scale completed by the subject.

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Official study title

Effects of Oxytocin on Neural Activation Patterns During Social Cognitive Tasks in Patients With Schizophrenia

Acronym: MEG

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Oct 6, 2015
Registry last updated
May 21, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.